News

81. Novartis Drug Afinitor Effective In Patients With Non-Cancerous Kidney Tumors Associated With TSC In Phase III Trial 9/26/2011
    A Phase III study of Afinitor (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
82. GE Healthcare To Invest $1B In New Oncology Solutions 9/20/2011
    GE Healthcare, the health business of General Electric, announced recently its plans to dedicate $1B of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research.
83. Clinical Labs And Pathology Groups Meet To Address The Rapidly Evolving Area Of Molecular Testing In Oncology 9/13/2011
    As molecular testing and genetic analysis continue to transform laboratory medicine, oncology is the area in which many of these novel diagnostics have the most powerful and attractive applications.
84. Conquer Cancer Foundation Presents Award To Dr. Schneider For His Research On New Biomarker In Breast Cancer Patients 9/13/2011
    The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) (formerly The ASCO Cancer Foundation) recently announced Bryan P. Schneider, M.D., as the recipient of the 2011 Advanced Clinical Research Award (ACRA) in Breast Cancer.
85. Social Media Valuable Tool For Recruiting Study Participants 9/6/2011
    Mayo Clinic has identified a new benefit of social media and online networking: a novel way to study rare diseases. Through patient-run websites dedicated to heart conditions and women's heart health, a team of cardiologists led by Sharonne Hayes, M.D., is reaching out to survivors of spontaneous coronary artery dissection, also known as SCAD, a poorly understood heart condition that affects just a few thousand Americans every year.
86. FDA Approves Adcetris To Treat Two Types Of Lymphoma 8/26/2011
    The U.S. Food and Drug Administration recently approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).
87. First Gene-Targeted Drug For Melanoma Approved By FDA 8/18/2011
    Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer. The Food and Drug Administration today announced the approval of Zelboraf, known as vemurafenib or PLX4032 during testing, well ahead of the approval deadline.
88. South Carolina Oncology Associates, VitalSource(SM) Sign GPO Agreement 8/1/2011
    Cardinal Health today announced that South Carolina Oncology Associates, the largest community oncology practice in the state, has selected VitalSource(SM) as its group purchasing organization (GPO) for infused oncology and other specialty medications.
89. INC Research And Debiopharm Group™ Announce Strategic Partnership 8/1/2011
    INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.
90. Virginia G. Piper Cancer Center, TGen Studying New Breast Cancer Drug 7/25/2011
    A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).